Melanocytes are destroyed, resulting in progressive skin depigmentation; satisfactory repigmentation may require months or years.
Target Population
Healthcare professionals involved in vitiligo care, including dermatologists, primary or internal medicine clinicians, nurse practitioners, and physician assistants.
Care Setting
International survey of healthcare professionals in 17 countries; findings describe reported diagnostic and management practices.
Key Highlights
Among self-identified nonspecialist HCPs, 82.2% reported trying to treat patients before referring them to a vitiligo specialist.
Lesion examination was reported very often or always by 74.1% of HCPs, while 65.1% reported examining the full body at that frequency.
Topical therapies were the most frequently prescribed treatment type, followed by light, laser, or phototherapy and oral medications.
Among HCPs prescribing each repigmentation treatment type at least sometimes, 45.5%–69.9% waited less than 3 months to assess outcomes, while 4.4%–14.4% waited more than 6 months.
The study findings indicate a need for HCP education addressing timely specialist referral or consultation and prolonged treatment to support repigmentation.
Guideline-Based Recommendations
Diagnosis
The article reports that HCPs commonly examine lesions and, less often, the full body; Wood’s lamp use was reported by 42.3% overall.
The article reports advice favoring rapid referral or specialist consultation for vitiligo management.
Management
The article states that treatment guidelines recommend treating vitiligo for a minimum of 6 months.
The study findings indicate a need for HCP education addressing prolonged treatment and timely specialist referral or consultation.
Monitoring & Follow-up
Many HCPs reported assessing treatment outcomes before 3 months; the article contrasts this with the stated guideline minimum treatment duration of 6 months.
Risks
The article describes delayed diagnosis and inadequate disease management as potentially prolonging vitiligo’s psychosocial burden.
The supplied excerpt identifies lack of treatment response, disease burden, safety or tolerability, cost, and patient preference among reasons for treatment interruptions.
Patient & Prescribing Data
The survey included 1203 HCPs: 1099 dermatologists and 104 primary care physicians. Eligibility included treating at least 10 patients with vitiligo during a typical 3-month period for dermatology practice, or at least 5 for primary or internal medicine practice.
HCPs reported frequent use of topical therapies (91.4%), light, laser, or phototherapy (65.7%), and oral medications (53.8%). Among HCPs prescribing each treatment type at least sometimes, 45.5%, 49.8%, and 69.9%, respectively, waited less than 3 months to assess outcomes; 14.4%, 9.6%, and 4.4% waited more than 6 months.
Clinical Best Practices
The article reports advice favoring timely referral or consultation with a vitiligo specialist.
The article reports a guideline recommendation to treat vitiligo for a minimum of 6 months.
The survey found that 60.8% of HCPs had previously advised a treatment interruption and 80.8% reported that patients had chosen one; reported reasons included lack of response, disease burden, safety or tolerability, cost, and patient preference.
The survey found that repigmentation was the most frequently reported treatment goal, followed by improvement of long-term clinical outcomes.
